Raquel Nunes

4.6k total citations
38 papers, 1.1k citations indexed

About

Raquel Nunes is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Raquel Nunes has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 13 papers in Cancer Research and 11 papers in Genetics. Recurrent topics in Raquel Nunes's work include Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (7 papers). Raquel Nunes is often cited by papers focused on Breast Cancer Treatment Studies (13 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (7 papers). Raquel Nunes collaborates with scholars based in United States, United Kingdom and Japan. Raquel Nunes's co-authors include Lyndsay N. Harris, Harold J. Burstein, Rebecca Gelman, Eric P. Winer, Craig A. Bunnell, Filipa Lynce, Sandra M. Swain, Paula D. Ryan, Mathew J. Ellis and Virginia F. Borges and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Raquel Nunes

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Raquel Nunes United States 14 816 333 303 171 164 38 1.1k
Rebecca Moroose United States 9 747 0.9× 190 0.6× 217 0.7× 191 1.1× 357 2.2× 23 1.0k
Tamer M. Fouad United States 19 683 0.8× 425 1.3× 101 0.3× 211 1.2× 291 1.8× 41 1.1k
Philippe Montcuquet France 16 581 0.7× 248 0.7× 66 0.2× 247 1.4× 332 2.0× 38 919
Elisabetta Pietri Italy 15 593 0.7× 364 1.1× 86 0.3× 320 1.9× 200 1.2× 27 909
H. S. Rugo United States 19 925 1.1× 318 1.0× 182 0.6× 274 1.6× 370 2.3× 107 1.3k
Chantal Bernard-Marty Belgium 14 845 1.0× 441 1.3× 191 0.6× 280 1.6× 247 1.5× 22 1.2k
Véronique D’Hondt France 21 781 1.0× 241 0.7× 110 0.4× 298 1.7× 335 2.0× 83 1.3k
Roberto Carmagnani Pestana United States 17 547 0.7× 192 0.6× 160 0.5× 217 1.3× 279 1.7× 52 1.1k
Elisa Zanardi Italy 16 355 0.4× 170 0.5× 102 0.3× 177 1.0× 420 2.6× 56 785
Erica Rappold United States 11 729 0.9× 125 0.4× 177 0.6× 319 1.9× 287 1.8× 28 1.1k

Countries citing papers authored by Raquel Nunes

Since Specialization
Citations

This map shows the geographic impact of Raquel Nunes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raquel Nunes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raquel Nunes more than expected).

Fields of papers citing papers by Raquel Nunes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raquel Nunes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raquel Nunes. The network helps show where Raquel Nunes may publish in the future.

Co-authorship network of co-authors of Raquel Nunes

This figure shows the co-authorship network connecting the top 25 collaborators of Raquel Nunes. A scholar is included among the top collaborators of Raquel Nunes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raquel Nunes. Raquel Nunes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamilton, Erika, S. Loibl, Thomas Bachelot, et al.. (2025). CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer. Future Oncology. 21(7). 795–806. 1 indexed citations
2.
Smith, Karen L., Hua‐Ling Tsai, David Lim, et al.. (2023). Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App. JCO Oncology Practice. 19(11). 981–989. 7 indexed citations
3.
Schlam, Ilana, Raquel Nunes, & Filipa Lynce. (2022). Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and Therapy. Volume 15. 471–478. 10 indexed citations
4.
Nunes, Raquel, Tal Sella, Kai Treuner, et al.. (2021). Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma. Clinical Cancer Research. 27(20). 5688–5696. 13 indexed citations
5.
Walsh, Elaine M., John H. Fetting, Deborah K. Armstrong, et al.. (2021). Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. 22(4). 319–325. 8 indexed citations
6.
Khoury, Katia, Filipa Lynce, Ana Barac, et al.. (2021). Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment. 185(3). 863–868. 20 indexed citations
7.
Lynce, Filipa & Raquel Nunes. (2021). Role of Platinums in Triple-Negative Breast Cancer. Current Oncology Reports. 23(5). 50–50. 22 indexed citations
8.
Denduluri, Neelima, Mark R. Somerfield, Mariana Chávez‐MacGregor, et al.. (2020). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(6). 685–693. 76 indexed citations
9.
Walsh, Elaine M., Raquel Nunes, Mary Wilkinson, & Cesar A. Santa‐Maria. (2020). Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. Current Oncology Reports. 22(12). 123–123. 5 indexed citations
10.
Bouça‐Machado, Raquel, Nilza Gonçalves, Patrícia Costa, et al.. (2020). Patients and Health Professional's Perspective of Functional Mobility in Parkinson's Disease. Frontiers in Neurology. 11. 575811–575811. 6 indexed citations
11.
12.
Lynce, Filipa, Ana Barac, Xue Geng, et al.. (2019). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research and Treatment. 175(3). 595–603. 102 indexed citations
13.
Tefera, Eshetu, Pia Herbolsheimer, Raquel Nunes, et al.. (2017). Video intervention increases participation of black breast cancer patients in therapeutic trials. npj Breast Cancer. 3(1). 36–36. 20 indexed citations
14.
Nunes, Raquel, Mihriye Mete, Pia Herbolsheimer, et al.. (2016). Genomic profiling of breast cancer in African-American women using MammaPrint. Breast Cancer Research and Treatment. 159(3). 481–488. 12 indexed citations
15.
Barac, Ana, Filipa Lynce, Karen L. Smith, et al.. (2016). Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Research and Treatment. 155(2). 285–293. 16 indexed citations
16.
Swain, Sandra M., Raquel Nunes, Carl Yoshizawa, Megan Rothney, & Amy P. Sing. (2015). Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age. Advances in Therapy. 32(12). 1222–1236. 26 indexed citations
17.
You, Fanglei, Lisa Roberts, Soonmo Peter Kang, et al.. (2008). Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. Journal of Hematology & Oncology. 1(1). 2–2. 28 indexed citations
18.
19.
Nunes, Raquel & Lyndsay N. Harris. (2002). The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer. Clinical Breast Cancer. 3(2). 125–135. 62 indexed citations
20.
Burstein, Harold J., Lyndsay N. Harris, Rebecca Gelman, et al.. (2002). Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study. Journal of Clinical Oncology. 21(1). 46–53. 221 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Moroose Breakdown of academic impact, for papers by Tamer M. Fouad Breakdown of academic impact, for papers by Philippe Montcuquet Breakdown of academic impact, for papers by Elisabetta Pietri Breakdown of academic impact, for papers by H. S. Rugo Breakdown of academic impact, for papers by Chantal Bernard-Marty Breakdown of academic impact, for papers by Véronique D’Hondt Breakdown of academic impact, for papers by Roberto Carmagnani Pestana Breakdown of academic impact, for papers by Elisa Zanardi Breakdown of academic impact, for papers by Erica Rappold
Rankless by CCL
2026